Skip to main content
SpringerLink
Log in

Recurrent Cytogenetic Abnormalities in Multiple Myeloma

  • Protocol
  • First Online:
Cancer Cytogenetics

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1541))

Abstract

Multiple myeloma is a heterogeneous disease. Its chromosomal abnormalities have been extensively studied with a view to accurate prognostication and personalized therapy. Here, we describe the techniques commonly employed for elucidating chromosomal aberrations, prognostic impact of recurrent chromosomal abnormalities, and recently updated risk stratification systems.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538–e548. doi:10.1016/S1470-2045(14)70442-5

    Article  PubMed  Google Scholar 

  2. Smith A, Howell D, Palmore R et al (2011) Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 105(11):1684–1692. doi:10.1038/bjc.2011.450

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Munshi NC, Anderson KC, Bergsagel PL et al (2011) Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 117(18):4696–4700. doi:10.1182/blood-2010-10-300970

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Mikhael JR, Dingli D, Roy V et al (2013) Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc 88(4):360–376. doi:10.1016/j.mayocp.2013.01.019

    Article  PubMed  Google Scholar 

  5. Palumbo A, Avet-Loiseau H, Olivia S et al (2015) Revised International staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol 33(26):2863–2869. doi:10.1200/JCO.2015.61.2267

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Dewald GW, Kyle RA, Hicks GA et al (1985) The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 66(2):380–390

    CAS  PubMed  Google Scholar 

  7. Hose D, Rème T, Hielscher T et al (2011) Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica 96(1):87–95. doi:10.3324/haematol.2010.030296

    Article  PubMed  Google Scholar 

  8. Pratt G (2002) Molecular aspects of multiple myeloma. Mol Pathol 55(5):273–283

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Avet-Loiseau H, Daviet A, Brigaudeau C et al (2001) Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique Hématologique. Blood 97(3):822–825

    Article  CAS  PubMed  Google Scholar 

  10. Kumar S, Fonseca R, Ketterling RP et al (2012) Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 119(9):2100–2105. doi:10.1182/blood-2011-11-390658

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. International Myeloma Working group (IMWG) (2016) Molecular classification of multiple myeloma. http://myeloma.org. Accessed 4 April 2016

  12. Fonseca R, Barlogie B, Bataille R et al (2004) Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 64(4):1546–1558

    Article  CAS  PubMed  Google Scholar 

  13. Smadja NV, Bastard C, Brigaudeau C et al (2001) Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98(7):2229–2238

    Article  CAS  PubMed  Google Scholar 

  14. Rajkumar SV (2012) Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 87(1):78–88

    Article  PubMed  PubMed Central  Google Scholar 

  15. Hartmann L, Biggerstaff JS, Chapman DB et al (2011) Detection of genomic abnormalities in multiple myeloma: the application of FISH analysis in combination with various plasma cell enrichment techniques. Am J Clin Pathol 136(5):712–720. doi:10.1309/AJCPF7NFLW8UAJEP

    Article  PubMed  Google Scholar 

  16. Paiva B, Almeida J, Pérez-Andrés M et al (2010) Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom 78(4):239–252. doi:10.1002/cyto.b.20512

    PubMed  Google Scholar 

  17. Ross FM, Avet-Loiseau H, Ameya G et al (2012) Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica 97(8):1272–1277

    Article  PubMed  PubMed Central  Google Scholar 

  18. Fonseca R, Bailey RJ, Ahmann GJ et al (2002) Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 100(4):1417–1427

    CAS  PubMed  Google Scholar 

  19. Kuehl WM, Bergsagel PL (2002) Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2(3):175–187

    Article  CAS  PubMed  Google Scholar 

  20. Avet-Loiseau H, Facon T, Grosbois B et al (2002) Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 99(6):2185–2191

    Article  CAS  PubMed  Google Scholar 

  21. Moreau P, Facon T, Leleu X et al (2002) Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 100(5):1579–1583

    Article  CAS  PubMed  Google Scholar 

  22. Moreau P, Attal M, Garban F et al (2007) Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia 21(9):2020–2024

    Article  CAS  PubMed  Google Scholar 

  23. Shaughnessy JD Jr, Zhan F, Burington BE et al (2007) A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109(6):2276–2284

    Article  CAS  PubMed  Google Scholar 

  24. Nair B, van Rhee F, Shaughnessy JD Jr et al (2010) Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood 115(21):4168–4173. doi:10.1182/blood-2009-11-255620

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Fonseca R, Blood E, Rue M et al (2003) Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101(11):4569–4575

    Article  CAS  PubMed  Google Scholar 

  26. Sawyer JR, Lukacs JL, Munshi N et al (1998) Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood 92(11):4269–4278

    CAS  PubMed  Google Scholar 

  27. Avet-Loiseau H, Leleu X, Roussel M et al (2010) Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 28(30):4630–4634. doi:10.1200/JCO.2010.28.3945

    Article  CAS  PubMed  Google Scholar 

  28. Avet-Louseau H, Daviet A, Sauner S et al (2000) Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br J Haematol 111(4):1116–1117

    Article  CAS  PubMed  Google Scholar 

  29. Chiecchio L, Protheroe RK, Ibrahim AH et al (2006) Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia 20(9):1610–1617

    Article  CAS  PubMed  Google Scholar 

  30. Rajan AM, Rajkumar SV (2015) Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J 5(10), e365. doi:10.1038/bcj.2015.92

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Hebraud B, Leleu X, Lauwers-Cances V et al (2014) Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia 28(3):675–679

    Article  CAS  PubMed  Google Scholar 

  32. Jacobson J, Barlogie B, Shaughnessy J et al (2003) MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants. Br J Haematol 122(3):430–440

    Article  PubMed  Google Scholar 

  33. Ola L, Gloria G, Ingemar T et al (2005) Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 107(3):904–906

    Article  Google Scholar 

  34. Robert K, Ellen R, Terry T et al (2007) Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 356:2582–2590. doi:10.1056/NEJMoa070389

    Article  Google Scholar 

  35. Rajkumar SV, Gupta V, Fonseca R et al (2013) Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 27(8):1738–1744. doi:10.1038/leu.2013.86

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Dimopoulos M, Kyle R, Fermand JP et al (2011) Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 117(18):4701–4705. doi:10.1182/blood-2010-10-299529

    Article  CAS  PubMed  Google Scholar 

  37. Chng WJ, Dispenzieri A, Chim CS et al (2014) IMWG consensus on risk stratification in multiple myeloma. Leukemia 28(2):269–277. doi:10.1038/leu.2013.247

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin, Hong Kong

    Nelson Chun Ngai Chan & Natalie Pui Ha Chan

Authors
  1. Nelson Chun Ngai Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Natalie Pui Ha Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nelson Chun Ngai Chan .

Editor information

Editors and Affiliations

  1. Haematology Division Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong Prince of Wales Hospital, Shatin, Hong Kong, China

    Thomas S.K. Wan

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media LLC

About this protocol

Cite this protocol

Chan, N.C.N., Chan, N.P.H. (2017). Recurrent Cytogenetic Abnormalities in Multiple Myeloma. In: Wan, T. (eds) Cancer Cytogenetics. Methods in Molecular Biology, vol 1541. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6703-2_23

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-6703-2_23

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-6701-8

  • Online ISBN: 978-1-4939-6703-2

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation